Approval · Notice of Compliance 14554 · 2013
TAFINLAR: Notice of Compliance 14554
Issued July 16, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14554
- Date
- July 16, 2013
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Protein kinase inhibitor
Products in this notice
Medicinal ingredients
- DABRAFENIB 50 MG per CAP
- DABRAFENIB 75 MG per CAP